Related references
Note: Only part of the references are listed.Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer
Stacy Loeb et al.
BJU INTERNATIONAL (2017)
Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer
Aaron A. Laviana et al.
CANCER (2016)
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score
Leander Van Neste et al.
EUROPEAN UROLOGY (2016)
Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer
Donna Pauler Ankerst et al.
JOURNAL OF UROLOGY (2016)
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
James McKiernan et al.
JAMA ONCOLOGY (2016)
Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer
Gisele H. J. M. Leyten et al.
CLINICAL CANCER RESEARCH (2015)
A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer
Dipen J. Parekh et al.
EUROPEAN UROLOGY (2015)
Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study
Richard J. Bryant et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer
Stacy Loeb et al.
JOURNAL OF UROLOGY (2015)
A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result
M. J. Donovan et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study
Richard J. Bryant et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
John T. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Variation of a test's sensitivity and specificity with disease prevalence
Mariska M. G. Leeflang et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2013)
Infective Complications After Prostate Biopsy: Outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, A Prospective Multinational Multicentre Prostate Biopsy Study
Florian M. E. Wagenlehner et al.
EUROPEAN UROLOGY (2013)
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range
William J. Catalona et al.
JOURNAL OF UROLOGY (2011)
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
A. Gupta et al.
BRITISH JOURNAL OF CANCER (2010)
Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication
Andrew Vickers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden
Andrew J. Vickers et al.
BMC MEDICINE (2008)
PCA3: A molecular urine assay for predicting prostate biopsy outcome
Ina L. Deras et al.
JOURNAL OF UROLOGY (2008)
Assessing prostate cancer risk: Results from the prostate cancer prevention trial
IM Thompson et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Share Paper
